ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC

Summary

This study aims to incorporate circulating tumor DNA (ctDNA)-minimal residual disease (MRD) to personalize the administration of consolidation toripalimab therapy in resected stage IB-IIIA non-small-cell lung cancer (NSCLC) after adjuvant therapy. Toripalimab is a humanized monoclonal antibody for human programmed cell death protein 1. Toripalimab was approved as a consolidation treatment after perioperative therapy in combination with chemotherapy for resectable stage III NSCLC.

Timeline

Start

2024-12-01

Primary completion

2026-12-01

Completion

2029-12-01

Drugs

Indications